---
title: "Laekna Advances Obesity Drug LAE102 With Positive Phase I Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296933979.md"
description: "Laekna (HK:2105) announced positive Phase I data for its obesity drug candidate LAE102, developed with Eli Lilly. The study in healthy postmenopausal women demonstrated a well-tolerated safety profile, dose-dependent improvements in lean body mass, and fat reduction. Consistent with earlier trials, Laekna has initiated a multiple dose expansion study in overweight subjects, with preliminary data expected in late 2026. Analysts maintain a 'Buy' rating with a HK$24.16 price target."
datetime: "2026-08-25T15:15:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296933979.md)
  - [en](https://longbridge.com/en/news/296933979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296933979.md)
generator: "portal-rs"
---

# Laekna Advances Obesity Drug LAE102 With Positive Phase I Data

Laekna, Inc. ( (HK:2105) ) just unveiled an announcement.

Laekna reported significant clinical progress for its obesity drug candidate LAE102 during the six months ended June 30, 2026, highlighting completion of a U.S. Phase I single ascending dose study in collaboration with Eli Lilly. The study in healthy postmenopausal women showed a well-tolerated safety profile and dose-dependent improvements in lean body mass and reductions in fat mass, alongside robust target engagement.

These Phase I results were consistent with an earlier multiple ascending dose study in overweight and obese subjects, which also demonstrated favorable body composition trends and no serious adverse events. Building on these data, Laekna has initiated a six-month Phase I multiple dose expansion study in overweight and obese subjects, with preliminary data expected in the second half of 2026, underscoring its ambitions in the competitive obesity drug market.

The most recent analyst rating on (HK:2105) stock is a Buy  
 with a HK$24.16 price target.  
 To see the full list of analyst forecasts on Laekna, Inc. stock,  
 see the HK:2105 Stock Forecast page. 

**More about Laekna, Inc.**

Laekna, Inc. is a Cayman Islands–incorporated biopharmaceutical company focused on developing innovative therapies, with a particular emphasis on metabolic and obesity-related conditions. Its pipeline includes internally discovered monoclonal antibodies such as LAE102, targeting pathways related to muscle regeneration and fat reduction for muscle-preserving weight control.

**Average Trading Volume:** 2,495,681

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$2.56B

Learn more about 2105 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)

## Related News & Research

- [Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.](https://longbridge.com/en/news/297565544.md)
- [Benjamin Edwards Inc. Has $34.94 Million Stake in Eli Lilly and Company $LLY](https://longbridge.com/en/news/298002862.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)
- [Aspen sees Mounjaro Africa sales above $124 million in 2027](https://longbridge.com/en/news/297915112.md)
- [Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118](https://longbridge.com/en/news/297573070.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**